Cart
sales@molnova.com
Takeda-6d
CAS No. 1125632-93-0
Takeda-6d( —— )
Catalog No. M27581 CAS No. 1125632-93-0
Takeda-6d is a novel, potent DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with IC50 of 7.0 nM and 2.2 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 256 | In Stock |
|
| 2MG | 130 | In Stock |
|
| 5MG | 188 | In Stock |
|
| 10MG | 282 | In Stock |
|
| 25MG | 463 | In Stock |
|
| 50MG | 631 | In Stock |
|
| 100MG | 848 | In Stock |
|
| 200MG | 1135 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTakeda-6d
-
NoteResearch use only, not for human use.
-
Brief DescriptionTakeda-6d is a novel, potent DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with IC50 of 7.0 nM and 2.2 nM, respectively.
-
DescriptionTakeda-6d is a novel, potent DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with IC50 of 7.0 nM and 2.2 nM, respectively.
-
In Vitro——
-
In VivoTakeda-6D (compound 6d) (10 mg/kg, Orally, once) shows sufficient oral bioavailability (F = 70.5%) in rats.Takeda-6D (0-10 mg/kg, Orally, once) significantly decreases phosphorylation levels of ERK1/24 h after oral administration in an A375 (BRAFV600E mutant) human melanoma xenograft model in rats.Takeda-6D (10 mg/kg, Orally, twice daily for 2 weeks) shows tumor regression with T/Cof ?7.0% without severe toxicity, and this tumor regression should include the efficacy based on the antiangiogenesis potency and BRAF inhibitory activity.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetVEGFR
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1125632-93-0
-
Formula Weight547.99
-
Molecular FormulaC27H19ClFN5O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN#CC1(CC1)c1cccc(C(Nc(cc(cc2)Oc(cc3)nc4c3nc(NC(C3CC3)=O)s4)c2F)=O)c1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Finn PJ, Sun L, Nampalli S, Xiao H, Nelson JR, Mamone JA, Grossmann G, Flick PK, Fuller CW, Kumar S. Synthesis and application of charge-modified dye-labeled dideoxynucleoside-5'-triphosphates to 'direct-load' DNA sequencing. Nucleic Acids Res. 2002 Jul 1;30(13):2877-85.
molnova catalog
related products
-
VEGFR-2-IN-6
VEGFR-2-IN-6 (WO 02/059110, example 64) is a potent inhibitor of VEGFR2, a crucial receptor involved in the regulation of angiogenesis .
-
Lenvatinib
Lenvatinib (E7080) is a multitargeted kinase inhibitor with IC50s of 4/5.2/22/46 nM for VEGFR2/VEGFR3/VEGFR1/FGFR1 in cell free assays.
-
Bucillamine
Bucillamine protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF.
